441 related articles for article (PubMed ID: 25918250)
1. Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the "THERAPY"phase 1-2 trial.
Assenat E; Azria D; Mollevi C; Guimbaud R; Tubiana-Mathieu N; Smith D; Delord JP; Samalin E; Portales F; Larbouret C; Robert B; Bibeau F; Bleuse JP; Crapez E; Ychou M; Pèlegrin A
Oncotarget; 2015 May; 6(14):12796-808. PubMed ID: 25918250
[TBL] [Abstract][Full Text] [Related]
2. Phase II study evaluating the association of gemcitabine, trastuzumab and erlotinib as first-line treatment in patients with metastatic pancreatic adenocarcinoma (GATE 1).
Assenat E; Mineur L; Mollevi C; Lopez-Crapez E; Lombard-Bohas C; Samalin E; Portales F; Walter T; de Forges H; Dupuy M; Boissière-Michot F; Ho-Pun-Cheung A; Ychou M; Mazard T
Int J Cancer; 2021 Feb; 148(3):682-691. PubMed ID: 33405269
[TBL] [Abstract][Full Text] [Related]
3. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial.
Xiong HQ; Rosenberg A; LoBuglio A; Schmidt W; Wolff RA; Deutsch J; Needle M; Abbruzzese JL
J Clin Oncol; 2004 Jul; 22(13):2610-6. PubMed ID: 15226328
[TBL] [Abstract][Full Text] [Related]
4. A phase I study of gemcitabine + dasatinib (gd) or gemcitabine + dasatinib + cetuximab (GDC) in refractory solid tumors.
Mettu NB; Niedzwiecki D; Rushing C; Nixon AB; Jia J; Haley S; Honeycutt W; Hurwitz H; Bendell JC; Uronis H
Cancer Chemother Pharmacol; 2019 Jun; 83(6):1025-1035. PubMed ID: 30895346
[TBL] [Abstract][Full Text] [Related]
5. Prospective study of cetuximab and gemcitabine in combination with radiation therapy: feasibility and efficacy in locally advanced pancreatic head cancer.
Fiore M; Trodella L; Valeri S; Borzomati D; Floreno B; Ippolito E; Trecca P; Trodella LE; D'Angelillo RM; Ramella S; Coppola R
Radiat Oncol; 2015 Dec; 10():255. PubMed ID: 26670587
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Gemcitabine With Trastuzumab and Pertuzumab After Prior Pertuzumab-Based Therapy Among Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: A Phase 2 Clinical Trial.
Iyengar NM; Smyth LM; Lake D; Gucalp A; Singh JC; Traina TA; DeFusco P; Fornier MN; Goldfarb S; Jhaveri K; Modi S; Troso-Sandoval T; Patil S; Ulaner GA; Jochelson M; Norton L; Hudis CA; Dang CT
JAMA Netw Open; 2019 Nov; 2(11):e1916211. PubMed ID: 31774522
[TBL] [Abstract][Full Text] [Related]
7. A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma.
Ko AH; Youssoufian H; Gurtler J; Dicke K; Kayaleh O; Lenz HJ; Keaton M; Katz T; Ballal S; Rowinsky EK
Invest New Drugs; 2012 Aug; 30(4):1597-606. PubMed ID: 21629990
[TBL] [Abstract][Full Text] [Related]
8. Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer.
Farhat F; Kattan JG; Ghosn M
Cancer Chemother Pharmacol; 2016 May; 77(5):1069-77. PubMed ID: 27059339
[TBL] [Abstract][Full Text] [Related]
9. An Intergroup Randomized Phase II Study of Bevacizumab or Cetuximab in Combination with Gemcitabine and in Combination with Chemoradiation in Patients with Resected Pancreatic Carcinoma: A Trial of the ECOG-ACRIN Cancer Research Group (E2204).
Berlin JD; Feng Y; Catalano P; Abbruzzese JL; Philip PA; McWilliams RR; Lowy AM; Benson AB; Blackstock AW
Oncology; 2018; 94(1):39-46. PubMed ID: 29040974
[TBL] [Abstract][Full Text] [Related]
10. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205.
Philip PA; Benedetti J; Corless CL; Wong R; O'Reilly EM; Flynn PJ; Rowland KM; Atkins JN; Mirtsching BC; Rivkin SE; Khorana AA; Goldman B; Fenoglio-Preiser CM; Abbruzzese JL; Blanke CD
J Clin Oncol; 2010 Aug; 28(22):3605-10. PubMed ID: 20606093
[TBL] [Abstract][Full Text] [Related]
11. In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption.
Larbouret C; Gaborit N; Chardès T; Coelho M; Campigna E; Bascoul-Mollevi C; Mach JP; Azria D; Robert B; Pèlegrin A
Neoplasia; 2012 Feb; 14(2):121-30. PubMed ID: 22431920
[TBL] [Abstract][Full Text] [Related]
12. Combined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xenografts.
Larbouret C; Robert B; Bascoul-Mollevi C; Penault-Llorca F; Ho-Pun-Cheung A; Morisseau S; Navarro-Teulon I; Mach JP; Pèlegrin A; Azria D
Ann Oncol; 2010 Jan; 21(1):98-103. PubMed ID: 19889608
[TBL] [Abstract][Full Text] [Related]
13. First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer.
Vaccaro V; Bria E; Sperduti I; Gelibter A; Moscetti L; Mansueto G; Ruggeri EM; Gamucci T; Cognetti F; Milella M
World J Gastroenterol; 2013 Jul; 19(28):4511-9. PubMed ID: 23901226
[TBL] [Abstract][Full Text] [Related]
14. Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma.
Abdel-Wahab R; Varadhachary GR; Bhosale PR; Wang X; Fogelman DR; Shroff RT; Overman MJ; Wolff RA; Javle M
J Hematol Oncol; 2018 May; 11(1):71. PubMed ID: 29843755
[TBL] [Abstract][Full Text] [Related]
15. A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance).
Halfdanarson TR; Foster NR; Kim GP; Meyers JP; Smyrk TC; McCullough AE; Ames MM; Jaffe JP; Alberts SR
Oncologist; 2019 May; 24(5):589-e160. PubMed ID: 30679315
[TBL] [Abstract][Full Text] [Related]
16. Multicenter phase II trial to investigate safety and efficacy of gemcitabine combined with cetuximab as adjuvant therapy in pancreatic cancer (ATIP).
Fensterer H; Schade-Brittinger C; Müller HH; Tebbe S; Fass J; Lindig U; Settmacher U; Schmidt WE; Märten A; Ebert MP; Kornmann M; Hofheinz R; Endlicher E; Brendel C; Barth PJ; Bartsch DK; Michl P; Gress TM;
Ann Oncol; 2013 Oct; 24(10):2576-2581. PubMed ID: 23897705
[TBL] [Abstract][Full Text] [Related]
17. Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial.
Cascinu S; Berardi R; Labianca R; Siena S; Falcone A; Aitini E; Barni S; Di Costanzo F; Dapretto E; Tonini G; Pierantoni C; Artale S; Rota S; Floriani I; Scartozzi M; Zaniboni A;
Lancet Oncol; 2008 Jan; 9(1):39-44. PubMed ID: 18077217
[TBL] [Abstract][Full Text] [Related]
18. Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer.
Harder J; Ihorst G; Heinemann V; Hofheinz R; Moehler M; Buechler P; Kloeppel G; Röcken C; Bitzer M; Boeck S; Endlicher E; Reinacher-Schick A; Schmoor C; Geissler M
Br J Cancer; 2012 Mar; 106(6):1033-8. PubMed ID: 22374460
[TBL] [Abstract][Full Text] [Related]
19. A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer.
Jhaveri K; Wang R; Teplinsky E; Chandarlapaty S; Solit D; Cadoo K; Speyer J; D'Andrea G; Adams S; Patil S; Haque S; O'Neill T; Friedman K; Esteva FJ; Hudis C; Modi S
Breast Cancer Res; 2017 Aug; 19(1):89. PubMed ID: 28764748
[TBL] [Abstract][Full Text] [Related]
20. HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer.
Miller K; Cortes J; Hurvitz SA; Krop IE; Tripathy D; Verma S; Riahi K; Reynolds JG; Wickham TJ; Molnar I; Yardley DA
BMC Cancer; 2016 Jun; 16():352. PubMed ID: 27259714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
